Streetbeat News

Products Services

RLYB

Rallybio Corporation presented nonclinical data on ENPP1 inhibition as a therapeutic approach for hypophosphatasia at the ASBMR 2024 Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:13 pm

MBX

MBX Biosciences presented the rationale and design of its Phase 2 Avail trial for MBX 2109, a potential long-acting parathyroid hormone peptide prodrug for hypoparathyroidism, at the ASBMR 2024 Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:11 pm

PRME

Prime Medicine shares rose following a strategic collaboration with Bristol Myers Squibb to develop reagents for ex vivo T-cell therapies. The company is also focusing its pipeline on high-value programs.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:10 pm

ATXS

Astria Therapeutics has received FDA Orphan Drug Designation for its drug navenibart, aimed at treating hereditary angioedema. The drug has shown promising results in reducing attack rates in clinical trials.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:10 pm

JNJ

Johnson & Johnson has launched the TECNIS Odyssey Intraocular Lens in the U.S., which provides cataract patients with precise vision at all distances and improved contrast in low light. The product has shown that 93% of patients achieve glasses-free vision.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:09 pm

ANVS

Annovis has filed three new patents for combination therapies involving Buntanetap with Trulicity and Viagra, aiming to enhance treatments for neurodegenerative disorders such as Alzheimer's and Parkinson's.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:07 pm

MRUS

Merus N.V. has initiated dosing in a Phase 3 trial (LiGeR-HN1) to evaluate petosemtamab in combination with pembrolizumab for treating PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma. The FDA has approved the dosage for further development.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:07 pm

EWZ

FMC

FMC Corporation has signed a distribution agreement with Ballagro Agro Tecnologia to expand its biological crop protection solutions in Brazil. This move strengthens FMC's biosolutions offering in a key market.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:06 pm

CLDI

Calidi Biotherapeutics has announced that the FDA has cleared Northwestern University's IND application for the CLD-101 clinical trial targeting high-grade glioma. The Phase 1/2 trial is expected to begin in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:06 pm

VEEE

Twin Vee PowerCats has announced a redesign of its popular 22-foot BayCat boat, which will launch in early 2025. The new design promises enhanced stability and smooth handling, aimed at improving water adventure experiences.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:06 pm